306 results about "Spike Protein" patented technology

The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins that include the spike protein or a portion thereof; peptidomimetics; vaccines; methods for vaccination and treatment of severe acute respiratory syndrome; antibodies; aptamers; and kits containing immunological compositions, or antibodies (or aptamers) that bind to the spike protein.

The subject invention relates in part to novel uses of bacteriophage tail spike proteins (TSPs). Some preferred uses are therapeutic uses in animals, such as chickens, against pathogenic bacteria, such as Salmonella. Fragments of the TSPs can also be used according to the subject invention, particularly protein fragments comprising the phage receptor binding domains (PRBDs), which recognize their hosts and facilitate infection. The binding domains are specific to unique surface structures on bacteria and may be used for a variety of applications according to the subject invention. We have shown that by utilizing these PRBDs, it is possible to exploit the long-established evolutionary relationship between bacteria and their viruses (ie bacteriophages) that specifically infect them. The subject invention also relates in part to novel, synthetic forms of tail spike proteins. In some preferred embodiments, these are hexamers.

The invention relates to a novel coronavirus vaccine and application thereof, in particular to a truncated Spike protein, a fusion protein containing the truncated Spike protein, a nucleic acid molecule containing a nucleotide sequence encoding the truncated Spike protein or the fusion protein, and a vector and a host cell containing the nucleic acid molecule. The invention further relates to a pharmaceutical composition containing the truncated Spike protein, fusion protein, nucleic acid molecule or vector.

The invention discloses a monoclonal antibody against a RBD region of novel coronavirus SARS-CoV-2 spike protein and application of the monoclonal antibody. The monoclonal antibody specifically bindsto the RBD region of the novel coronavirus SARS-CoV-2 spike glycoprotein. The monoclonal antibody comprises complementarity determining regions of CDRH1, CDRH2, CDRH3 of a heavy chain variable regionand complementarity determining regions of CDRL1, CDRL2, CDRL3 of a light chain variable region. According to the monoclonal antibody against the RBD region of the novel coronavirus SARS-CoV-2 spike protein, the titer is high, the specificity is higher, efficient expressing can be achieved, the monoclonal antibody can specifically bind to the RBD region of the spike protein on the surface of the novel coronavirus SARS-CoV-2 and can be used for the detection of the ovel coronavirus SARS-CoV-2, certain toxicity of the novel coronavirus can be neutralized and reduced, and the effect of preventingor / and treating the novel coronavirus pneumonia is achieved.

The invention provides a recombinant baculovirus with the surface displaying a porcine epidemic diarrhea virus S protein, and a preparation method thereof. The virus adopts PEDV spike protein S1 gene as antigen gene, the recombinant virus is constructed by using an insect baculovirus vector expression system, and an S1 protein is successfully expressed and displayed on the surface of the virus. The recombinant virus is used to immunize and inoculate mice as a PEDV pseudo-virus vaccine, and serum neutralization test and lymphocyte propagation experiment analysis shows that the recombinant virus can arouse an effective immune protection effect.

The invention discloses a monoclonal antibody for a novel coronavirus virus SARS-CoV-2 spike protein RBD region and an application of the monoclonal antibody, and belongs to the field of cell immunology and the like. The monoclonal antibody is specifically combined with a novel coronavirus virus SARS-CoV-2 spike glycoprotein RBD region, and comprises complementarity determining regions CDRH1, CDRH2 and CDRH3 of a heavy chain variable region and complementarity determining regions CDRL1, CDRL2 and CDRL3 of a light chain variable region; the monoclonal antibody for the novel coronavirus virus SARS-CoV-2 spike protein RBD region is high in titer and specificity, can be efficiently expressed, can be specifically combined with the spike protein RBD region on the surface of the novel coronavirusvirus SARS-CoV-2, can be used for detecting the novel coronavirus virus SARS-CoV-2, and has a broad application prospect. Certain novel coronavirus virus toxicity can be neutralized and weakened, andthe effect of preventing or / and treating novel coronavirus virus pneumonia is achieved.

The invention provides a method for preparing a recombinant novel coronavirus Spike protein. The invention firstly provides application of the following polypeptides as a signal peptide in preparationof recombinant novel coronavirus Spike protein: polypeptides composed of the amino acid sequence as shown in SEQ ID No. 10. By adopting a specific signal peptide, an expression vector containing polynucleotide for encoding the recombinant novel coronavirus Spike protein is constructed, and mammalian cells are transfected to secrete and express the recombinant novel coronavirus Spike protein, so that the secretory expression level of the Spike protein in HEK293 cells can be remarkably improved.

The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins that include the spike protein or a portion thereof; peptidomimetics; vaccines; methods for vaccination and treatment of severe acute respiratory syndrome; antibodies; aptamers; and kits containing immunological compositions, or antibodies (or aptamers) that bind to the spike protein.

The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins that include the spike protein or a portion thereof; peptidomimetics; vaccines; methods for vaccination and treatment of severe acute respiratory syndrome; antibodies; aptamers; and kits containing immunological compositions, or antibodies (or aptamers) that bind to the spike protein.